Arvinas, Inc. (NASDAQ:ARVN) has received an average rating of “Buy” from the nineteen ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and sixteen have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $129.38.
ARVN has been the subject of a number of research reports. Roth Capital raised their price objective on Arvinas from $120.00 to $135.00 and gave the stock a “buy” rating in a research report on Monday, August 9th. SVB Leerink initiated coverage on Arvinas in a research report on Thursday, October 14th. They issued an “outperform” rating and a $115.00 price objective for the company. Zacks Investment Research downgraded Arvinas from a “buy” rating to a “hold” rating in a research report on Tuesday, October 12th. Stifel Nicolaus initiated coverage on Arvinas in a research report on Wednesday, September 29th. They issued a “buy” rating and a $115.00 price objective for the company. Finally, Oppenheimer upgraded Arvinas from a “market perform” rating to an “outperform” rating in a research report on Thursday, November 4th.
In related news, insider Ian Taylor sold 20,000 shares of the firm’s stock in a transaction on Monday, November 15th. The stock was sold at an average price of $84.04, for a total transaction of $1,680,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Timothy M. Shannon sold 36,411 shares of Arvinas stock in a transaction on Tuesday, September 7th. The shares were sold at an average price of $89.09, for a total value of $3,243,855.99. The disclosure for this sale can be found here. Over the last three months, insiders sold 276,899 shares of company stock valued at $24,752,298. 6.45% of the stock is currently owned by insiders.
NASDAQ:ARVN traded down $2.02 during mid-day trading on Friday, hitting $74.44. 1,661,135 shares of the company’s stock traded hands, compared to its average volume of 376,327. The firm has a 50 day moving average of $83.96 and a two-hundred day moving average of $83.80. Arvinas has a 12 month low of $25.00 and a 12 month high of $108.46. The firm has a market capitalization of $3.94 billion, a price-to-earnings ratio of -19.59 and a beta of 1.95.
Arvinas (NASDAQ:ARVN) last announced its earnings results on Wednesday, November 3rd. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of $2.13 by ($3.07). Arvinas had a negative net margin of 794.97% and a negative return on equity of 27.02%. The business had revenue of $9.28 million for the quarter, compared to the consensus estimate of $26.89 million. During the same quarter in the previous year, the company earned ($0.79) EPS. Arvinas’s revenue for the quarter was up 22.2% compared to the same quarter last year. On average, equities analysts forecast that Arvinas will post -3.55 earnings per share for the current year.
Arvinas, Inc is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.
Further Reading: Black Swan
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.